Happy Nice Mall

An expert panel from the Centers for Disease Control and Prevention on Thursday voted to favor COVID vaccines other than Johnson & Johnson, based on growing evidence that the company’s vaccines are now linked to dozens of cases and trigger at least a rare blood clot disorder. Nine deaths last year.

Some committee members expressed hope that exceptions could be made in cases where people do not have access to the more popular shots from Moderna or Pfizer-BioNTech, or want the Johnson & Johnson vaccine despite being informed of a rare but potentially high risk. serious side effect.

The panel’s vote effectively discourages vaccine providers and adults from using Johnson & Johnson’s vaccine. Data presented to the committee on Thursday showed a higher risk for a blood clotting condition than had been previously reported to the panel.

The recommendation that the CDC still has to decide whether to accept is the latest pushback for a vaccine that has largely fallen out of favor in the United States. The company’s vaccine lost its early promise as a traditional, single, finished format that would be easy to administer in more isolated or rural communities and among people who are timid about taking two doses.

about 16 million people In the United States, 73 million fully immunized with Moderna’s vaccine and 114 million with Pfizer-BioNTech vaccines received the Johnson & Johnson vaccine as primary immunization. Among Americans who took the booster, only 1.5 percent chose the Johnson & Johnson shot.

Earlier this week, the Food and Drug Administration updated guide published He spoke about the risks of blood clotting disorders associated with Johnson & Johnson’s vaccine, but reiterated that the benefits outweigh the risks.

The panel’s recommendation comes amid an increase in virus cases caused by the Delta coronavirus variant and Omicron, the latest version that has already become dominant in some countries and is spreading rapidly in the United States.

Several laboratory experiments show that a single dose of Johnson & Johnson needles can provide little defense against Omicron infection. Company said last month He said he tested blood samples from clinical trial participants who were shot as a booster to see how the vaccine-induced antibodies acted against Omicron.

At Thursday’s meeting of the Vaccine Practices Advisory Committee, CDC officials into detail About the coagulation-related syndrome identified in 54 people vaccinated before the end of August in the United States. Overall, the rate of the condition was 3.8 cases per million people given the vaccine. This is higher than previously thought.

An increased risk for the condition is linked to the Johnson & Johnson vaccine and the shot from AstraZeneca, which is not authorized in the United States. Not affiliated with Moderna or Pfizer vaccines.

A pediatrician at Ohio State University, one of the committee members, Dr. Pablo Sanchez said he is turning families away from the Johnson & Johnson vaccine.

“I don’t recommend it to any of my patients’ families and I tell them to stay away from it,” he said.

Evidence is increasingly showing that a single dose of Johnson & Johnson vaccine provides little protection against infection. federal health officials authorized in October boosters for people who received a single shot of the company’s vaccine at least two months ago. By allowing a “mix and match” approach, they let people get a second shot of Pfizer or Moderna.

So far, most Johnson & Johnson recipients who have received a booster have turned to other vaccines, and no one who has been initially vaccinated with other vaccines has chosen Johnson & Johnson as booster.

Despite their recommendations, a number of panelists said it was important to have the Johnson & Johnson vaccine available as an option.

A representative of the American College of Physicians and an assistant professor of clinical biomedical science at Florida Atlantic University, Dr. “Still, it’s really important that we don’t completely eliminate this vaccine,” said Jason Goldman.

He said the final advice “should be clear, simple and concise so that we can get more people vaccinated.”

Johnson & Johnson executive Dr. Penny Heaton said the vaccine has made a “significant difference” in saving lives as the US has surpassed 800,000 Covid-19 deaths.

“The risk of Covid-19 is of course much higher than the risk observed after vaccination, and cases of Covid-19 continue to rise this holiday season,” he said.

CDC officials discussed the coagulation-related syndrome, which was identified in 54 people in the United States who were vaccinated before the end of August. Overall, the rate of the condition was 3.8 cases per million people given the vaccine. This is higher than previously thought.

The risk for the condition known as thrombosis with thrombocytopenia syndrome, which can cause internal bleeding, was highest in women aged 30-49, occurring in approximately 1 in 100,000 recipients in this age group. A CDC official, Dr. Isaac See said the rate at which the condition is normally expected in the general population is unknown.

Of all Johnson & Johnson vaccine recipients diagnosed with the condition, 36 were admitted to the intensive care unit, with the longest hospital stay at 132 days. Eight of them died. The ninth person has died since September.

Dr. “We were very impressed to review these cases for how quickly the condition deteriorated and resulted in death,” See said.

The ages of the deceased ranged from 28 to 62. Seven of them were women and they were all white. Obesity was the most common underlying medical condition. Dr. See said two of the deceased had no known medical problems.

Dr. See said additional cases have been identified since previous CDC meetings due to delays in reporting and delays in identifying and approving vaccine-related diseases.

An increased risk for the condition is linked to the Johnson & Johnson vaccine and the shot from AstraZeneca, which is not authorized in the United States. Not affiliated with Moderna or Pfizer vaccines.

In April, shortly after Johnson & Johnson’s vaccine became available in the United States, federal officials briefly discontinued use of the vaccine over concerns about the risk of blood clots. Other countries have also taken action to pause vaccine use, with some suggesting that women in at-risk age groups be advised to seek other vaccines.

Internationally, a CDC review covering 16 high-income countries showed others put the brakes on adenovirus vector vaccines like Johnson & Johnson’s. This category also includes a vaccine from AstraZeneca that is not used in the United States, but has been discontinued in five countries and is subject to preferential recommendation in seven. Finland, Denmark and Slovenia have discontinued use of the Johnson & Johnson vaccine due to the risk of blood clots, and four other countries rank use lower than mRNA vaccines such as Pfizer-BioNTech and Moderna.

a CDC presentation showed that despite coagulation concerns, the Johnson & Johnson vaccine prevented thousands of Covid hospitalizations in the US compared to three to a dozen cases of coagulation syndrome, depending on age group. Those over the age of 64 avoided most hospital stays. If 1 million had been vaccinated with the Johnson & Johnson vaccine, approximately 57,000 people would have avoided hospitalization.